Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental combo for advanced bone cancer shows early promise but study halted

NCT ID NCT06438783

First seen Jan 09, 2026 · Last updated Apr 29, 2026 · Updated 15 times

Summary

This early-phase trial tested a combination of two drugs (TQB2928 injection and anlotinib capsules) in 20 adults with advanced bone cancer (osteosarcoma) or other solid tumors that had returned or spread. The goal was to see if the combination could shrink tumors or delay cancer growth. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Beijing cancer hospital

    Beijing, Beijing Municipality, 100142, China

  • Beijing jishuitan hospital

    Beijing, Beijing Municipality, 100035, China

  • Hunan cancer hospital

    Changsha, Hunan, 410031, China

  • Pekjing university people's hospital

    Beijing, Beijing Municipality, 100044, China

  • Tianjin medical university cancer institute&hospital

    Tianjin, Tianjin Municipality, 300181, China

Conditions

Explore the condition pages connected to this study.